About
Calcimedica, Inc. Common Stock (NASDAQ:CALC) — investor relations, events, news, and company updates on 6ix.
Latest News
Mar 3 2026
CalciMedica Reports 2025 Financial Results and Provides Clinical Updates
Jan 28 2026
CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation
Nov 12 2025
CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
Nov 12 2025
CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension
Nov 10 2025
CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025
Financials
Revenue
$0
Market Cap
$9.21 M
EPS
-1.97
Translate